Lutathera

Pharma

CHMP signs off on GSK's comeback ADC cancer drug Blenrep

Among several decisions this week, Europe's CHMP has recommended GSK's Blenrep for approval for patients with relapsed or refractory multiple myeloma.

Kevin Dunleavy May 23, 2025 11:23am

legal criminal lady justice court case law trial

Novartis filed patent lawsuits in defense of radiopharma meds

Nov 4, 2024 10:48am

Novartis brings isotope production in house amid global shortage

Sep 4, 2024 11:24am

Novartis eyes $1B Lutathera acceleration with first-line win

Jan 19, 2024 10:00am

Novartis commits $85M to build radiotherapy plant in China

Dec 1, 2023 11:06am

With trial win, Novartis eyes first-line use for Lutathera

Sep 25, 2023 10:33am